New GlobalData Medical Devices Reports29 Dec 2011 • by Natalie Aster
External Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017. The global market for external defibrillators, which was valued at $1.5 billion in 2010, is forecast to grow at a Compound Annual Growth Rate (CAGR) of 6% over the period 2010 - 2017 to exceed $2.2 billion by 2017. The market for manual defibrillators used in hospital setups will grow at a rate of 4% to about $896.5m in 2017, while the professional automated external defibrillators (AED) market is expected to surpass the manual defibrillator market, growing at a CAGR of 11% to reach about $836.9m in 2017. The expected growth in the global external defibrillator market can be attributed to high global incidence rates of sudden cardiac arrest (SCA), government legislations promoting external defibrillator installation programs and opportunities for penetration in emerging markets.
The US external defibrillator market, valued at around $620.9m in 2010, is the largest market by region for these devices. The second largest market by revenue is Japan, with revenues worth $317m in 2010. Large-scale contracts for the public installation of AEDs along with increasing public awareness have been instrumental in pushing government legislation mandating initiatives to install AEDs at all high-risk public places, and at the same time to equip hospitals and EMS teams with the minimum number of required defibrillators.
Drug Eluting Balloons (DEB) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017. The Drug Eluting Balloons (DEBs) market is expected to grow at a Compound Annual Growth Rate (CAGR) of 8.1% to $127m by 2017. The Percutaneous Transluminal Coronary Angioplasty (PTCA) DEB market is also expected to grow at 8.1% to $103m by 2017. The Percutaneous Transluminal Angioplasty (PTA) DEB market is expected to grow at a CAGR of 8.2% to reach $24m 2010-2017. The market will be driven by increased physician adoption as long term clinical data is released and as the device is adopted for new indications such as Peripheral Vascular Disease (PVD). The US Food and Drug Administration (FDA) product approvals over the next two to three years are also expected to boost future uptake future because the US is an important region for the interventional cardiology devices market. DEBs fulfill a huge unmet need in the market and so adoption is expected to increase at the same rate as physician awareness.
Small Vessel Disease (SVD), bifurcated lesions, In-Stent Restenosis (ISR) and PVD represent nearly a $2 billion market potential. In addition, the complications associated with long term antiplatelet therapy such as the risk of bleeding and contraindications limit the use of current interventions. Cost and patient compliance is also a factor promoting the use of DEBs.
Report Per Price: US$ 3.500,00 (Single User License)
More research reports by the publisher can be found at GlobalData page.
To order the report or ask for sample pages contact firstname.lastname@example.org